Lineage Acquires NeuroAirmid and Huntington Program

Company Lineage Cell Therapeutics; NeuroAirmid Therapeutics Event Type Completed acquisition Modality Allogeneic neural stem-cell transplantation Asset HUNT1 / REGEN4HD program Target Not applicable (cell replacement) Disease Area Huntington disease Summary Lineage Cell Therapeutics completed its acquisition of NeuroAirmid Therapeutics on November 12, adding a neural…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *